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Global burden of disease, in terms of both mortality and
morbidity, is increasing [1, 2]. Ageing of population and better
management of acute conditions are significant contributors,
yet there is much more to be done. Also, there are numerous
situations in clinical practice where we are left with limited
evidence and various degrees of uncertainty regarding how
to deliver the best medical practice to our patients. This in
particular applies for emergency and intensive care where
decisions need to be taken within minutes if not seconds;
it is therefore not surprising that practicing physician may
take suboptimal ways to handle the clinical challenges [3].
Heart failure serves as a good example and in fact this is
only cardiovascular condition with increasing prevalence [4].
By adding various comorbidities to the main disease (e.g.,
anaemia, chronic obstructive pulmonary disease, chronic
kidney disease, and cancer, all potentially with bodywasting),
you end up with an individual prone to deterioration of
one or more components of its health status [5–9]. An
additional challenge in acute deterioration of chronic disease
is iatrogenic due to complex pharmacological therapy; in its
essence, very best incentive for a stable patient can get really
cumbersome for patient and a clinician once faced with fail-
ing organ functions, a common scenario in emergency and
intensivemedicine.With changes in pharmacokinetics, phar-
macodynamics effects are unpredictable, as may be the drug-
drug and in particular drug-disease or drug-disease-drug
interactions [10–12]. Adding the immediate-acting drugs we
usually use in this setting, we are indeed exploring the
limited-evidence land and outcomes are less predictable.
This, in fact, reminds us once again that we need to consider
every patient as an individual with peculiarities and specific
response to disease/acute condition and management we
employ. Herein, we need to get back to the basics or to the fact
that Homo mensura est (Homo mensura est stands for man
is the measure said by Protagoras (Greek: Π𝜌𝜔𝜏𝛼𝛾o´𝜌𝛼𝜍, c.
490–c. 420 BC)) or, in other words, that medicine is an art
[13]. Yet, this coin has two sides: one is the patient whilst the
other one is the practicing physician. And both of them are
humans, with all pros and cons. Once in hospital due to acute
condition or with critical illness, a comprehensive evaluation
of cardiovascular system is crucial for reliable assessment
of disease severity and management steps. Here, the other
side of the coin, namely, the practicing physician, is taking
Centre stage. Again, Homo mensura est is more true than
ever.With all difficulties to assess the cardiovascular function
and to take decisions in best of patient interest, one needs to
rely on parameters one can reliably assess and interpret. This
largely depends on one’s training, experience, and confidence
with particular monitoring tools or biomarkers [14–16].
Unfortunately, clinical practice tells us, despite all efforts by
the clinical community [17, 18], that we do not meet the
standards of good clinical practice [19]. Counterintuitively,
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the development of less invasive methods for assessment of
haemodynamic parameters (that all have limitations in the
critically ill) did not change patterns of invasive haemo-
dynamic monitoring. Despite availability, echocardiography
remains critically underused for these purposes. The lesson
learned from the FENICE study [19] should be considered as
an important signal to fine-tune our preclinical and clinical
training to optimize patient assessment and management.
In acute conditions, we are indeed left with limited-
evidence-based medicine. But are there ways to overcome
this? Primarily, we should not have prejudices how to handle
our patients. The story of beta-blockers in heart failure
might serve as a useful example. Initially these drugs were
contraindicated, but in current heart failure guidelines, the
largest wealth of evidence for prognostic benefit lies within
them. Indeed, we are trying to break some long-lasting taboos
of misconception through use of these pharmacological
agents in obstructive pulmonary disease and during acute
deterioration [20–23]. A similar frontier is sepsis, for exam-
ple, [24]. In sepsis, a closer cooperation between scientific
communities, clinicians, and regulatory agencies is required
in order to meet future challenges. Some other communities
have already paved the way and it is our mission to follow in
their footsteps [25]. This issue tried to address some of these
aspects. Indeed, we feel that education aiming to optimize
patient assessment and to understand the pathophysiological
rationale of our actions is crucial in our striving to improve
patient outcome. In clinical practice, various options for
haemodynamic assessment should be available. Accurate
measurement gives us reliable findings that are the basis
for timely diagnosis and therapeutic decisions, tailored to
individual patient. We would therefore like to promote this
special issue and the two review articles by J. Benes et al.
and H. A. Gaspar and S. S. Morhy in particular; furthermore,
we would once again like to underline the Protagoras quote
Homo mensura est. Although generally applicable, the sig-
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